Transpek Industry Ltd
TRANSPEKTranspek Industry Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is in a downtrend (47 weeks in) while the P/E sits at the 53rd percentile of its own 11-year range. Underneath, the last four quarters read deteriorating — profit −65.8% year on year, and 201% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Transpek Industry Ltd trades at ₹1,313, in a downtrend and 47 weeks into that stage. That is +13.8% against its own 200-day average. It sits at 71% of a 52-week range of ₹909 to ₹1,478. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a downtrend — week 47 of stage 4, confirmed. At ₹1,313 it trades +13.8% versus its 200-day average and sits at 71% of its 52-week range (₹909–₹1,478).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +257% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Transpek Industry Ltd trades at 16.2× P/E, mid-range by its own standards (53rd percentile). Its long-run median P/E is 15.4×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 16.2× is mid-range by its own standards (53rd percentile), against a long-run median of 15.4× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −6.3% against a −19.7% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −6.6%/yr price move, ~+14.3%/yr came from earnings growth and ~−20.9 pp from the multiple (compressing); over 10y, of the +11.0%/yr price move, ~+8.0%/yr came from earnings growth and ~+3.0 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Transpek Industry Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue and profit growth are shrinking (revenue growth −10.3% latest (single-quarter readings) against +30.0% at its 12-quarter best), ROCE slipping at 8.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −4.5% | −9.1% | +12.9% | +8.1% |
| Profit | −6.1% | −17.9% | +14.9% | +8.2% |
| EPS | −6.3% | −18.2% | +14.4% | +8.5% |
| Share price | −19.7% | −9.4% | −6.6% | +11.0% |
4-Factor Sector Score
38.4/100 — rank 23 of 27 in Speciality Chemicals · 77% evidence confidence
Transpek Industry Ltd scores 38.4 out of 100 against the 27 companies it is compared with in Speciality Chemicals, ranking 23. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 8.1 + 9.1 + 13.8 + 7.4 = 38.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Transpek Industry Ltd reported ₹148 Cr of revenue in the Mar 26 quarter, −10.3% year on year. Over 10 years it has compounded at 8.1% a year. The last full year, FY26, came in at ₹621 Cr. The last four reported quarters add to ₹621 Cr.
FY26 revenue came in at ₹621 Cr (−4.5% on the year), capping 10 years at 8.1% compound. The latest quarter (Mar 26) printed ₹148 Cr, −10.3% year on year.
Pace check: the last four quarters averaged −4.3% growth against the decade's 8.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −4.4% over the last 4 quarters against +3.5%/yr over the last 8 — rolling over; TTM profit −6.3% vs +8.8%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Transpek Industry Ltd's operating margin is 12.0% in the Mar 26 quarter, −7.5 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 21.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 12.0%, −7.5 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–21.0%.
🚨 Why the margin moved: operating margin went −7.5 pp year on year while gross margin went +2.8 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Transpek Industry Ltd earned ₹6.6 Cr of net profit in the Mar 26 quarter, −65.8% year on year. Full-year FY26 profit was ₹46.0 Cr. The 10-year compound rate is 8.2%. That is 4.4% of the quarter's revenue. The same quarter a year earlier earned ₹19.3 Cr.
Mar 26 profit was ₹6.6 Cr, −65.8% year on year. On the full year, FY26 printed ₹46.0 Cr (−6.1%), and the 10-year compound rate is 8.2%.
🚨 Why profit moved: revenue contributed −10.3% and the margin −7.5 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +9.1% vs revenue −4.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 201% of Transpek Industry Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was ₹135 Cr of operating cash against ₹49.0 Cr of profit. After ₹12.0 Cr of capital spending, ₹123 Cr was left as free cash.
FY25: operating cash of ₹135 Cr against reported profit of ₹49.0 Cr, leaving free cash of ₹123 Cr after ₹12.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 201% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 201%: the cash cycle tightened 19 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Transpek Industry Ltd's cash conversion cycle runs 64 days in FY26, down from 83 days in FY21. Capital spending ran ₹96.0 Cr over the last 3 years. At FY26 sales of ₹621 Cr each day of that cycle holds about ₹1.7 Cr, so roughly ₹109 Cr sits inside the business at any moment.
FY26: debtors at 88 days, inventory at 63 days — roughly 2.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 64 days, tighter than FY21's 83.
The full loop: cash goes out to suppliers and production on day 0; stock waits 63 days to sell; customers pay about 88 days after that; and suppliers themselves are paid at 87 days — netting out to the 64-day cycle.
In money terms: at FY26 sales of ₹621 Cr, each day of the cycle holds about ₹1.7 Cr — so the 64-day loop keeps roughly ₹109 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹96.0 Cr over the last 3 fiscal years against ₹137 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹5.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Transpek Industry Ltd earns a ROCE of 8% in FY26. That is up from a trough of 7% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 7.4% net margin on 0.62× asset turns.
FY26 ROCE is 8%, recovered from a FY21 trough of 7% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 7.4% net margin × 0.62× asset turns × 1.31× balance-sheet leverage ≈ 6.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Transpek Industry Ltd carries ₹60.0 Cr of borrowings against ₹768 Cr of equity in FY26, a debt-to-equity of 0.08. Operating profit covers the interest bill 12×. Over 5 years borrowings went from ₹111 Cr to ₹60.0 Cr. Capital spending ran ₹96.0 Cr across the last 3 of those years.
FY26: borrowings of ₹60.0 Cr against equity of ₹768 Cr — a debt-to-equity of 0.08. Operating profit covers the interest bill 12×. Over 5 years borrowings went from ₹111 Cr to ₹60.0 Cr while capital spending ran ₹96.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Transpek Industry Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved −0.2 points over the same window, to 57.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −0.7 points over 8 quarters to 1.1%; Promoters: −0.2 points over 8 quarters to 57.3%; Foreign institutions: +0.0 points over 8 quarters to 0.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Transpek Industry Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Sunshield Chemicals Ltd530845 | 70.0/100Favorable setup72% evidence | TURNING | 28.4/35 Revenue 20.5% · PAT 100% · OPM change 5 pp 83% evidence | 16.3/25 ROCE 19.9% · OPM 15% 76% evidence | 11.2/20 P/E 35.1× · PEG — 50% evidence | 14.1/20 RS sector 2.3% · RS bench 22.4% · 1Y 59.8%11 of 11 weeks ahead 70% evidence |
| Exact sum: 28.4 + 16.3 + 11.2 + 14.1 = 70 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Privi Speciality Chemicals LtdPRIVISCL | 64.2/100Mixed-positive evidence75% evidence | LEADER | 24.9/35 Revenue 21.6% · PAT 62.1% · OPM change -1 pp 95% evidence | 17.8/25 ROCE 22.3% · OPM 23% 76% evidence | 9.3/20 P/E 40.4× · PEG — 15% evidence | 12.2/20 RS sector 2.6% · RS bench 19.1% · 1Y 45.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 17.8 + 9.3 + 12.2 = 64.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Pidilite Industries LtdPIDILITIND | 63.6/100Mixed-positive evidence90% evidence | TURNING | 21.8/35 Revenue 11.1% · PAT 17.9% · OPM change 3 pp 88% evidence | 19.6/25 ROCE 31% · OPM 23% 100% evidence | 7.6/20 P/E 66.6× · PEG 3.73 100% evidence | 14.6/20 RS sector 5.2% · RS bench 7.2% · 1Y 11.5%6 of 10 weeks ahead 70% evidence |
| Exact sum: 21.8 + 19.6 + 7.6 + 14.6 = 63.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Vikram Thermo (India) Ltd530477 | 63.1/100Mixed-positive evidence63% evidence | TURNING | 23.1/35 Revenue 7% · PAT 100% · OPM change 7.1 pp 83% evidence | 19.2/25 ROCE 36.4% · OPM 31.7% 76% evidence | 8.9/20 P/E 20× · PEG — 50% evidence | 11.9/20 RS sector — · RS bench 40.3% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 23.1 + 19.2 + 8.9 + 11.9 = 63.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Yasho Industries LtdYASHO | 62.6/100Mixed-positive evidence87% evidence | TURNING | 29.3/35 Revenue 34.1% · PAT 100% · OPM change 7 pp 100% evidence | 8.7/25 ROCE 8.9% · OPM 24% 100% evidence | 12.1/20 P/E 80.7× · PEG 1.15 65% evidence | 12.5/20 RS sector -2.4% · RS bench 109.3% · 1Y 97.1%11 of 11 weeks ahead 70% evidence |
| Exact sum: 29.3 + 8.7 + 12.1 + 12.5 = 62.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Tatva Chintan Pharma Chem LtdTATVA | 61.4/100Mixed-positive evidence93% evidence | BREAKING OUT | 30.7/35 Revenue 41.1% · PAT 100% · OPM change 4 pp 100% evidence | 6.6/25 ROCE 7.1% · OPM 19% 100% evidence | 4.8/20 P/E 79.8× · PEG 5.63 65% evidence | 19.3/20 RS sector 21.3% · RS bench 40.9% · 1Y 56.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 30.7 + 6.6 + 4.8 + 19.3 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Panama Petrochem LtdPANAMAPET | 57.5/100Mixed-positive evidence90% evidence | TURNING | 17.5/35 Revenue 9.7% · PAT 14.5% · OPM change 2 pp 88% evidence | 13.3/25 ROCE 19.2% · OPM 11% 100% evidence | 15.8/20 P/E 12.9× · PEG 0.55 100% evidence | 10.9/20 RS sector -5.8% · RS bench 42.3% · 1Y 31.6%10 of 11 weeks ahead 70% evidence |
| Exact sum: 17.5 + 13.3 + 15.8 + 10.9 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Kronox Lab Sciences LtdKRONOX | 56.7/100Mixed-positive evidence61% evidence | 13.6/35 Revenue 1% · PAT 8.2% · OPM change 6.8 pp 83% evidence | 21.2/25 ROCE 36% · OPM 36.4% 95% evidence | 11.1/20 P/E 20.3× · PEG — 15% evidence | 10.8/20 RS sector — · RS bench 5.4% · 1Y — 25% evidence | |
| Exact sum: 13.6 + 21.2 + 11.1 + 10.8 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Alkyl Amines Chemicals LtdALKYLAMINE | 56.5/100Mixed-positive evidence73% evidence | TURNING | 20.5/35 Revenue 17.4% · PAT 100% · OPM change -0.1 pp 71% evidence | 18.9/25 ROCE 41.3% · OPM 14.5% 95% evidence | 9.3/20 P/E 48.2× · PEG — 50% evidence | 7.8/20 RS sector -14.6% · RS bench 3% · 1Y -18.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.5 + 18.9 + 9.3 + 7.8 = 56.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Aether Industries LtdAETHER | 55.9/100Mixed-positive evidence100% evidence | BREAKING OUT | 24.5/35 Revenue 34.4% · PAT 34.3% · OPM change -1 pp 100% evidence | 10.6/25 ROCE 11.9% · OPM 31% 100% evidence | 4.3/20 P/E 85.2× · PEG 8.9 100% evidence | 16.5/20 RS sector 30.6% · RS bench 51.5% · 1Y 97%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 10.6 + 4.3 + 16.5 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Aarti Industries LtdAARTIIND | 53.7/100Mixed-positive evidence100% evidence | FADING | 27.9/35 Revenue 27% · PAT 100% · OPM change 3 pp 100% evidence | 8.8/25 ROCE 6.8% · OPM 16% 100% evidence | 6.9/20 P/E 34× · PEG 2.05 100% evidence | 10.1/20 RS sector -0.7% · RS bench 15.3% · 1Y 13.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 27.9 + 8.8 + 6.9 + 10.1 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Vinati Organics LtdVINATIORGA | 50.0/100Mixed-positive evidence76% evidence | ASLEEP | 12.2/35 Revenue 5.1% · PAT 5.7% · OPM change -5 pp 95% evidence | 17.4/25 ROCE 19.8% · OPM 24% 76% evidence | 13.3/20 P/E 30.2× · PEG — 50% evidence | 7.1/20 RS sector -4.1% · RS bench -14% · 1Y -30.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.2 + 17.4 + 13.3 + 7.1 = 50 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13DMCC Speciality Chemicals LtdDMCC | 49.4/100Mixed-negative evidence76% evidence | FADING | 20.4/35 Revenue 34.8% · PAT 27% · OPM change -2.1 pp 83% evidence | 11.4/25 ROCE 15.3% · OPM 10% 95% evidence | 10.5/20 P/E 25.8× · PEG — 15% evidence | 7.1/20 RS sector -11.1% · RS bench 2.9% · 1Y -9.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 11.4 + 10.5 + 7.1 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Fineotex Chemical LtdFCL | 47.6/100Mixed-negative evidence94% evidence | TURNING | 18.7/35 Revenue 91.5% · PAT 41% · OPM change -2 pp 100% evidence | 13.0/25 ROCE 18.3% · OPM 16% 100% evidence | 3.3/20 P/E 37.4× · PEG 4.19 100% evidence | 12.6/20 RS sector -2.3% · RS bench 42% · 1Y 45.8%11 of 11 weeks ahead 70% evidence |
| Exact sum: 18.7 + 13 + 3.3 + 12.6 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Grauer & Weil (India) LtdGRAUWEIL | 46.9/100Mixed-negative evidence96% evidence | TURNING | 15.5/35 Revenue 4.9% · PAT 4.4% · OPM change 8 pp 88% evidence | 16.8/25 ROCE 21.4% · OPM 17% 100% evidence | 7.7/20 P/E 21.2× · PEG 4.01 100% evidence | 6.9/20 RS sector -15% · RS bench -1.6% · 1Y -24.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 16.8 + 7.7 + 6.9 = 46.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Platinum Industries LtdPLATIND | 46.8/100Mixed-negative evidence70% evidence | ASLEEP | 16.7/35 Revenue 14.5% · PAT 0% · OPM change 4 pp 83% evidence | 12.7/25 ROCE 15.7% · OPM 12% 95% evidence | 10.8/20 P/E 23.7× · PEG — 15% evidence | 6.6/20 RS sector -10.6% · RS bench -9% · 1Y -23.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 12.7 + 10.8 + 6.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Neogen Chemicals LtdNEOGEN | 44.0/100Mixed-negative evidence90% evidence | LEADER | 15.3/35 Revenue 18.1% · PAT 6.1% · OPM change 2 pp 100% evidence | 6.9/25 ROCE 6.5% · OPM 19% 100% evidence | 5.1/20 P/E 156× · PEG — 50% evidence | 16.7/20 RS sector 15.8% · RS bench 33.3% · 1Y 28.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 6.9 + 5.1 + 16.7 = 44 · Decision use: Price leads the evidence: RS versus the benchmark is 33.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Vishnu Chemicals LtdVISHNU | 43.5/100Mixed-negative evidence100% evidence | FADING | 15.5/35 Revenue 16.5% · PAT 17.2% · OPM change -1 pp 100% evidence | 11.8/25 ROCE 16.3% · OPM 15% 100% evidence | 6.2/20 P/E 27.6× · PEG 2.82 100% evidence | 10.0/20 RS sector -2.3% · RS bench 13.3% · 1Y 23.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 11.8 + 6.2 + 10 = 43.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Anupam Rasayan India LtdANURAS | 41.5/100Mixed-negative evidence78% evidence | ASLEEP | 20.6/35 Revenue 64.5% · PAT 38.8% · OPM change -7 pp 83% evidence | 10.3/25 ROCE 7.4% · OPM 22% 76% evidence | 8.0/20 P/E 80.8× · PEG — 50% evidence | 2.6/20 RS sector -17.4% · RS bench -3.6% · 1Y 5.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 10.3 + 8 + 2.6 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Chemcon Speciality Chemicals LtdCHEMCON | 40.4/100Mixed-negative evidence77% evidence | TURNING | 16.1/35 Revenue 15.7% · PAT -3.5% · OPM change 1.2 pp 83% evidence | 8.8/25 ROCE 6.4% · OPM 11.8% 95% evidence | 11.5/20 P/E 27.2× · PEG — 50% evidence | 4.0/20 RS sector -21.7% · RS bench -12% · 1Y -17.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 16.1 + 8.8 + 11.5 + 4 = 40.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Galaxy Surfactants LtdGALAXYSURF | 40.1/100Mixed-negative evidence90% evidence | TURNING | 12.0/35 Revenue 24.2% · PAT -13.1% · OPM change -2 pp 88% evidence | 12.9/25 ROCE 13.5% · OPM 9% 100% evidence | 8.9/20 P/E 24.8× · PEG 4.39 100% evidence | 6.3/20 RS sector -12.1% · RS bench -4.1% · 1Y -25.1%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12 + 12.9 + 8.9 + 6.3 = 40.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Amines & Plasticizers LtdAMNPLST | 40.0/100Mixed-negative evidence77% evidence | TURNING | 9.4/35 Revenue -13.8% · PAT -14.3% · OPM change 2 pp 83% evidence | 15.2/25 ROCE 16.7% · OPM 15% 95% evidence | 8.5/20 P/E 29.9× · PEG — 50% evidence | 6.9/20 RS sector -19.4% · RS bench 3.8% · 1Y -12.3%10 of 10 weeks ahead 70% evidence |
| Exact sum: 9.4 + 15.2 + 8.5 + 6.9 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Transpek Industry Ltdthis pageTRANSPEK | 38.4/100Mixed-negative evidence77% evidence | TURNING | 8.1/35 Revenue -4.4% · PAT -6.3% · OPM change -7.5 pp 83% evidence | 9.1/25 ROCE 8.3% · OPM 12% 95% evidence | 13.8/20 P/E 16.2× · PEG — 50% evidence | 7.4/20 RS sector -19.7% · RS bench 8% · 1Y -19.4%3 of 10 weeks ahead 70% evidence |
| Exact sum: 8.1 + 9.1 + 13.8 + 7.4 = 38.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24Paushak LtdPAUSHAKLTD | 36.2/100Mixed-negative evidence81% evidence | TURNING | 11.5/35 Revenue 15.4% · PAT -15.7% · OPM change -1 pp 95% evidence | 9.9/25 ROCE 8.3% · OPM 31% 95% evidence | 8.3/20 P/E 36.6× · PEG — 50% evidence | 6.5/20 RS sector -27.5% · RS bench 7.3% · 1Y -3.2%6 of 11 weeks ahead 70% evidence |
| Exact sum: 11.5 + 9.9 + 8.3 + 6.5 = 36.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Clean Science & Technology LtdCLEAN | 34.1/100Adverse evidence94% evidence | ASLEEP | 4.4/35 Revenue -0.4% · PAT -13.8% · OPM change -5 pp 100% evidence | 17.6/25 ROCE 20.6% · OPM 36% 100% evidence | 8.6/20 P/E 33.5× · PEG 6.24 100% evidence | 3.5/20 RS sector -24.4% · RS bench -18% · 1Y -40.9%2 of 10 weeks ahead 70% evidence |
| Exact sum: 4.4 + 17.6 + 8.6 + 3.5 = 34.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Thirumalai Chemicals LtdTIRUMALCHM | 24.8/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue -15.4% · PAT -80% · OPM change -1.4 pp 62% evidence | 0.9/25 ROCE -3.1% · OPM 1.4% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.8/20 RS sector -15.9% · RS bench -22.9% · 1Y -40.9%1 of 10 weeks ahead 70% evidence |
| Exact sum: 9.1 + 0.9 + 10 + 4.8 = 24.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Amal LtdAMAL | 50.0/100Thin evidence · provisional50% evidence | 19.8/35 Revenue 72.5% · PAT 19.1% · OPM change -31.6 pp 53% evidence | 15.1/25 ROCE 36.3% · OPM 12.9% 57% evidence | 10.9/20 P/E 23× · PEG — 15% evidence | 4.2/20 RS sector -18.2% · RS bench -26.3% · 1Y -51.4%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 19.8 + 15.1 + 10.9 + 4.2 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Transpek Industry Ltd's share price today?
Transpek Industry Ltd trades at ₹1,313, −19.7% over the past year. The company is valued at ₹738 Cr. The stock sits at 71% of its 52-week range of ₹909–₹1,478, +13.8% versus its 200-day average. On the tape, the price is in a downtrend, 47 weeks in. — as of 31 July 2026.
What were Transpek Industry Ltd's latest quarterly results?
Transpek Industry Ltd reported revenue of ₹148 Cr and net profit of ₹6.6 Cr for the Mar 26 quarter. Revenue fell 10.3% and profit fell 65.8% year on year. Earnings per share were ₹11.78. The operating margin was 12.0%, 7.5 pp lower than a year earlier. — as of 31 July 2026.
What is Transpek Industry Ltd's revenue?
Transpek Industry Ltd reported revenue of ₹148 Cr in the Mar 26 quarter, −10.3% year on year. For the full FY26 fiscal year, revenue was ₹621 Cr (−4.5%). Over the last 10 years revenue compounded at 8.1% a year. — as of 31 July 2026.
What is Transpek Industry Ltd's profit?
Transpek Industry Ltd earned ₹6.6 Cr of net profit in the Mar 26 quarter, −65.8% year on year. Full-year FY26 profit was ₹46.0 Cr. The operating margin ran 12.0% in the latest quarter. — as of 31 July 2026.
What is Transpek Industry Ltd's market cap?
Transpek Industry Ltd's market capitalisation is ₹738 Cr at a share price of ₹1,313. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Transpek Industry Ltd's P/E ratio?
Transpek Industry Ltd trades at a P/E of 16.2×, at the 53rd percentile of its own 11-year range, against a long-run median of 15.4×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Transpek Industry Ltd pay a dividend?
Yes — Transpek Industry Ltd's dividend payout was 24% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Transpek Industry Ltd overvalued?
On its own history, Transpek Industry Ltd looks mid-range against its own history: its P/E of 16.2× sits at the 53rd percentile of its 11-year range (long-run median 15.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Transpek Industry Ltd growing?
Not right now — Transpek Industry Ltd's latest numbers are shrinking: latest-quarter revenue −10.3% year on year, profit −65.8%, and the margin −7.5 pp at 12.0%. The 10-year compound rates are 8.1% (revenue) and 8.2% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Transpek Industry Ltd performing?
Transpek Industry Ltd is in a downtrend, 47 weeks in. Its latest quarter's revenue fell 10.3% and profit fell 65.8% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Transpek Industry Ltd in?
Deteriorating — revenue and profit growth are shrinking (revenue growth −10.3% latest (single-quarter readings) against +30.0% at its 12-quarter best), ROCE slipping at 8.0%. The read comes from the last 12 quarters of growth (revenue growth −10.3% latest, profit growth −65.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Transpek Industry Ltd in an uptrend?
No — the price is in a downtrend (week 47 of stage 4), trading +13.8% versus its 200-day average and at 71% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Transpek Industry Ltd beating the market?
On recent form, yes — Transpek Industry Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +257% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will Transpek Industry Ltd's share price go up?
This page publishes no price forecast for Transpek Industry Ltd. What it measures instead: the share price is ₹1,313, the price is in a downtrend 47 weeks in. Its P/E of 16.2× sits at the 53rd percentile of its own 11-year range. — as of 31 July 2026.
Who owns Transpek Industry Ltd?
Promoters hold 57.3% of Transpek Industry Ltd, foreign institutions 0.0%, domestic institutions 1.1% and the public 41.6% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Transpek Industry Ltd have too much debt?
No — Transpek Industry Ltd's debt-to-equity is 0.08, and operating profit covers the interest bill 12×. FY26 borrowings were ₹60.0 Cr against equity of ₹768 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Transpek Industry Ltd's capex?
Transpek Industry Ltd spent ₹96.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹32.0 Cr, with ₹5.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Transpek Industry Ltd's cash flow?
Transpek Industry Ltd generated ₹135 Cr of operating cash flow in FY25 and ₹123 Cr of free cash flow after ₹12.0 Cr of capital spending. Reported profit that year was ₹49.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Transpek Industry Ltd's profit real cash?
Yes — over the last 3 fiscal years, 201% of Transpek Industry Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹135 Cr against reported profit of ₹49.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Transpek Industry Ltd in its business cycle?
Transpek Industry Ltd's FY26 operating margin was 15.0%, against a 13-year band of 10.0%–21.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 12.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Transpek Industry Ltd story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Transpek Industry Ltd a stock worth studying right now?
This is not investment advice. The machine read: Transpek Industry Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.